SCHEDULE: FMR LLC Discloses 9.9% Stake in Day One Biopharma
Beneficial Ownership Report (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 9.9% beneficial ownership stake in Day One Biopharmaceuticals Inc. as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson reported beneficial ownership of 10,097,668.36 shares of common stock in DAY ONE BIOPHARMACEUTICALS INC.
- This represents 9.9% of the company's outstanding common stock.
- The filing is an Amendment No. 4 to a previous Schedule 13G, indicating an update to their reported ownership.
- The ownership is reported as of September 30, 2025.
- FMR LLC holds sole voting power over 10,083,983.00 shares and sole dispositive power over 10,097,668.36 shares.
- Abigail P. Johnson, as a Director, Chairman, and Chief Executive Officer of FMR LLC and a predominant owner of its voting shares, is deemed to beneficially own the same aggregate amount of shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements from the issuer.
Future Outlook
This filing does not provide any forward-looking statements or guidance from Day One Biopharmaceuticals Inc.
Industry Context
This filing indicates continued significant institutional interest in Day One Biopharmaceuticals Inc. by a major asset manager, FMR LLC (Fidelity). Such substantial ownership by a prominent investment firm can signal confidence in the company's long-term prospects within the biotechnology and pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Company Management: Awareness of a large, stable institutional shareholder can impact strategic decisions and investor relations.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney is incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney is incorporated by reference. |
| 2025-09-30 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-11-04 | Signature date of the Schedule 13G filing. |
Keywords
Day One Biopharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.